Bioventus Inc. (NASDAQ: BVS) is a Healthcare company (Medical - Devices) with a market capitalization of $726M. The Maz Rating grades it against the other companies in its sector.
Bioventus Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $10.60, Bioventus Inc. trades at 12.4x trailing earnings, 1.2x sales and 3.0x book value, with an EV/EBITDA of 9.2. Over the last twelve months it generated about $590M of revenue and $58M of net income. It runs a gross margin of 68.3%, an operating margin of 10.1% and a net margin of 9.8%. It shows return on equity of 27.2%, return on invested capital of 11.0% and a free cash flow yield of 11.8%. On the balance sheet: a debt-to-equity ratio of 1.02 and a current ratio of 1.68. Over the past 52 weeks the share price ranged from $6.47 to $15.89, with a beta of 0.62.
Bioventus Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 5 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Bioventus Inc. (BVS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 25.5% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.41% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 25.5% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.41% / 33% · Receivables / Mkt Cap (36m) 15.3% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 25.5% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.41% / 33.33% · Receivables / Mkt Cap (24m) 15.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 39.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 5.49% / 33.33% · Receivables / Avg Assets (4Q) 19.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 34.1% / 33.33% · (Cash+ST Inv) / Total Assets 4.56% / 33.33% · (Cash+Recv) / Total Assets 25.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Bioventus Inc. (BVS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Bioventus Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Bioventus Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 26, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.